FDA: Alzheimer Drugs Must Show Clinical Benefit
(MedPage Today) -- In a long-awaited draft guidance document, the FDA said it would not accept biomarker or imaging-based outcomes as a primary endpoint in pivotal trials for Alzheimer's disease drugs.
Tags:
FDA: Alzheimer Drugs Must Show Clinical Benefit,
Alzheimer's Disease Latest News